Instituto de Salud Carlos III -ko ikertzaileekin lankidetzan egindako argitalpenak (9)

2024

  1. Immunogenicity of a third dose with mRNA-vaccines in the ChAdOx1-S/BNT162b2 vaccination regimen against SARS-CoV-2 variants

    iScience, Vol. 27, Núm. 9

  2. Novel risk loci for COVID-19 hospitalization among admixed American populations

    eLife, Vol. 13

  3. Omicron XBB.1.16-Adapted Vaccine for COVID-19: Interim Immunogenicity and Safety Clinical Trial Results

    Vaccines, Vol. 12, Núm. 8

2023

  1. A second update on mapping the human genetic architecture of COVID-19

    Nature

  2. Altered Red Blood Cell Fatty Acid and Serum Adipokine Profiles in Subjects with Obesity

    Biomedicines, Vol. 11, Núm. 12

2022

  1. Immune response and reactogenicity after immunization with two-doses of an experimental COVID-19 vaccine (CVnCOV) followed by a third-fourth shot with a standard mRNA vaccine (BNT162b2): RescueVacs multicenter cohort study

    eClinicalMedicine, Vol. 51

  2. Immunogenic dynamics and SARS-CoV-2 variant neutralisation of the heterologous ChAdOx1-S/BNT162b2 vaccination: Secondary analysis of the randomised CombiVacS study

    eClinicalMedicine, Vol. 50

  3. Novel genes and sex differences in COVID-19 severity

    Human molecular genetics, Vol. 31, Núm. 22, pp. 3789-3806

2021

  1. Immunogenicity and reactogenicity of BNT162b2 booster in ChAdOx1-S-primed participants (CombiVacS): a multicentre, open-label, randomised, controlled, phase 2 trial

    The Lancet, Vol. 398, Núm. 10295, pp. 121-130